Viral Hepatitis Drugs & ARVs

Drug-drug interactions between Viral Hepatitis Drugs and ARVs



Legend

↑                  Potential elevated exposure of the hepatitis therapy
↓                  Potential decreased exposure of the hepatitis therapy
↔                No significant effect
D                 Potential decreased exposure of ARV drug
E                  Potential elevated exposure of ARV drug

ATV/c         ATV co-formulated with COBI (300/150 mg qd)
DRV/c         DRV co-formulated with COBI (800/150 mg qd)
CAB/RPV   CAB and RPV im long acting injections (PK and/or QT interactions shown are with RPV)

Numbers refer to decreased or increased AUC as observed in drug-drug interaction studies.
First/second numbers refer to AUC changes for EBR/GZR or GLE/PIB or SOF/LDV or SOF/VEL.
First/second/third numbers refer to AUC changes for SOF/VEL/VOX

 

Interactions with ABC, FTC, 3TC, ZDV

ABC, FTC, 3TC, ZDV: no clinically relevant interactions expected.

 

Interactions with ibalizumab

None

 

Comments

  1. Monitoring of renal function recommended due to increase of tenofovir concentration if the regimen contains TDF.
  2. Study details are with DRV/r qd. DRV bid has not been studied and should be used with caution as voxilaprevir concentrations may increase more than with DRV qd (this would be of further significance in cirrhotic patients). Monitoring of renal function recommended due to increase of tenofovir concentrations if the regimen contains TDF.

 

Further Information

For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to: http://www.hiv-druginteractions.org (University of Liverpool)